ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.24 (−49.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Arcturus Therapeutics Holdings Inc. saw revenue fall 76.0% to $29.37M over the twelve months to Jun 30, 2026. Free cash flow was -$72.82M.
Revenue
$29.37M
-76.0% vs. a year earlier
Operating income
-$102.30M
TTM Q2 2026
Free cash flow
-$72.82M
TTM Q2 2026
EPS, diluted
-$3.31
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $296.17M
- P/E ratio
- –
- Price to sales
- 10.09
- Price to book
- 1.72
- Dividend yield
- –
- Free cash flow yield
- -24.59%
Fundamentals
- Revenue
- $29.37M
- Net income
- -$93.28M
- EPS, diluted
- -$3.31
- Free cash flow
- -$72.82M
- Book value per share
- $6.04
- Diluted shares
- 28M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$29.37M-76.0% YoY
Operating income
-$102.30M
Net income
-$93.28M
EPS, diluted
-$3.31
Free cash flow
-$72.82M
Reported periodTrailing twelve months